Abstract 2097P
Background
OM is one of the main adverse events during chemotherapy, affecting around 40% of pts; it is characterized by an inflammation and ulceration of the oral mucous membranes that can lead to oral pain, impaired nutritional intake, local or systemic infections and lower quality of life. Only few strategies are available for its prevention and management. FP-based tp can cause OM due to their cytotoxic effect on mucosal cells inducing DNA double strand brakes and ROS production, empowered by TNF-alfa release. In our retrospective monocentric study we evaluated clinical and hematological RFs which could help us to identify early those patients who might benefit the most from a preventive strategy.
Methods
We evaluated incidence, management and possible RFs for OM (such as diabetes, smoke, BMI and blood inflammation markers) on 174 pts treated with a FP-based tp during a typical month in our DH. Statistical analysis has been conducted using Chi-square test and Fisher’s exact test. Pts have been informed about risk of developing OM and we subsequently managed the symptom on the basis of its severity according to CTCAE.
Results
48 pts developed OM. We found a higher OM incidence in smoker pts (60.5% vs 21.4% in non smoker, p<0.0001) and in overweight pts (39.7% vs 24.1% in pts with normal weight, p=0.0381). We also demonstrated a correlation between a higher OM severity and diabetes diagnosis (71% vs 29.8% in non diabetic pts, p=0.0330). No statistically significant correlation emerged between OM incidence/severity and any of the blood values tested (blood cells values, NLR, PLR, creatinine). 20 pts had ≥G2 OM and received local and/or systemic therapies, while 3 pts needed a treatment suspension. Median time to resolution was 28 days. 6 pts still had OM of various severity grade at the time of our analysis.
Conclusions
Smoke and overweight could be RFs for OM incidence of any grade during a FP-based treatment, while a diabetes diagnosis seemed to be related with a higher severity of OM, but not with its incidence. In view of the above, it might be useful to recommend accurate oral hygiene and a preventive strategy in accordance with MASCC guidelines in these subgroups of pts.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2076P - Topical diclofenac for prevention of HFS in patients receiving capecitabine monotherapy: An exploratory subgroup analysis of the D-ToRCH phase III trial
Presenter: Akhil Santhosh
Session: Poster session 06
2077P - A randomized, placebo-controlled trial assessing the efficacy and safety of the combination of superoxide dismutase, alpha lipoic acid, vitamin B12, B1, B2, B6, E, Mg, Zn and a fatty acid for 6 months in the management of chemotherapy induced neuropathic pain
Presenter: Triantafylos Didangelos
Session: Poster session 06
2078P - Evaluation of chemotherapy-induced nausea and vomiting beyond the delayed phase: Results of a survey of healthcare providers in Japan
Presenter: Florian Scotté
Session: Poster session 06
2079P - Naloxegol for the treatment of opioid-induced constipation in patients with cancer pain: A pooled analysis of real-world studies (NALOPOOL)
Presenter: Maria del Carmen Beato Zambrano
Session: Poster session 06
2080P - Incidence and risks of intravenous chemotherapy-induced neutropenia (ICIN) in oncology: A multicenter retrospective cohort study on real-life data
Presenter: Olivia Rohr
Session: Poster session 06
2081P - The therapeutic effect of anti-inflammatory tripeptide cream on hand-foot syndrome related to anticancer drugs: A prospective, randomized, placebo-controlled pilot trial
Presenter: Yaewon Yang
Session: Poster session 06
2082P - TASMAN: An international survey on the knowledge, aTtitudes and clinical pAtternsS of use of Medical Cannabis for caNcer care
Presenter: Marco Filetti
Session: Poster session 06
2083P - Association between VTE location and risk of recurrent, bleeding and death in the international prospective TESEO SEOM cancer cohort
Presenter: Rocío Martín Lozano
Session: Poster session 06
2084P - Cardiovascular (CV) mortality among metastatic cancer patients: A retrospective cohort study
Presenter: Irbaz Riaz
Session: Poster session 06